[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:multicentric-castleman-disease":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":39,"states":44},"Multicentric Castleman Disease",5,[7,15,21,27,33],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07085039","Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease",[11],"Phase 2","RECRUITING","2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.210854Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05907759","Daratumumab for Relapsed\u002FRefractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease",[11],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:26.949844Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT04968288","Natural History of KSHV-Associated Multicentric Castleman s Disease",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.275783Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":31,"content_modified":32},"NCT05663502","Collecting Blood and Tissue Sample Donations for Research for HIV\u002FAIDS-Related Cancers",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.369655Z",{"nct_id":34,"title":35,"phases":36,"status":12,"updated_at":37,"content_modified":38},"NCT00006518","Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer",[],"2026-08-26T02:17:21.315591Z","2026-05-13T02:55:06.028653Z",[40],{"biomarker":41,"count":42,"slug":43},"KSHV",3,"kshv",[45],{"state":46,"count":47,"slug":48},"Maryland",4,"maryland"]